> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest FDA Warning Letters
- URL: https://www.fdaweb.com/latest-fda-warning-letters-31/
- Published: 2020-07-28T12:00:00.000Z
- Updated: 2026-09-14T16:22:43.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5147299

FDA has posted its latest batch of Warning Letters. They can be accessed by clicking on the link following each letter.  

**Eosera, Inc.**, Fort Worth, TX (7/13): FDA inspected the firm in January and cited significant GMP violations for finished pharmaceuticals. For example, Eosera failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications. It also failed to follow a written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates. To view the letter, click [here](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eosera-inc-605500-07132020?ref=fdaweb.com).  

**Tender Corp.**, Littleton, NH (7/23): FDA inspected the firm 11/2019 and cited significant GMP violations for finished pharmaceuticals. For example, Tender failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards. It also failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity. To view the letter, click [here](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tender-corporation-599789-07232020?ref=fdaweb.com).